StreetAlpha.app
Home › Stocks › AURA

Aura Biosciences, Inc. (AURA)

Healthcare
$6.87
▼ −1.58%
LAST CLOSE · NOV 20

Aura Biosciences develops bel sar, an experimental cancer drug for eye and bladder tumors that is still in clinical trials. It last closed at $6.87 on Nov 20, down 1.58% on the day. The next earnings report for AURA is expected around Mon, Mar 29, 2027. For the quarter ended Sep 2026, AURA reported EPS of -$0.29. Over its last 8 reports the stock moved an average of 5.1% the session after earnings. Over the last 12 months AURA insiders bought $0 of stock on the open market and sold $39.9M, according to SEC Form 4 filings.

AI Auto Pilots
Is AURA in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold AURA.

Key Stats

Last 12 months
Results
Net income
−$136.9M
EPS (diluted)
−$1.59
Free cash flow
−$109.7M
Valuation
Market cap
$715.0M
104.1M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$41.7M
At Sep 30
Shareholder equity
$287.4M
Shares outstanding
104.1M
At Nov 4
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$35.3M−$35.3MFY2021FY2022: −$58.8M−$58.8MFY2022FY2023: −$76.4M−$76.4MFY2023FY2024: −$86.9M−$86.9MFY2024FY2025: −$106.2M−$106.2MFY2025

From AURA's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 9). Last 12 months adds up the four latest quarters.

Next report
Mar 29
Estimated date · Time not announced
Reported EPS
-$0.29
Quarter ended Sep 2026
Year ago EPS
-$0.40
Same quarter last year
Revenue
—
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.52Dec '24Mar 2025: -$0.55Mar '25Jun 2025: -$0.47Jun '25Sep 2025: -$0.40Sep '25Dec 2025: -$0.37Dec '25Mar 2026: -$0.50Mar '26Jun 2026: -$0.48Jun '26Sep 2026: -$0.29Sep '26Latest -$0.29
Revenue by quarter
Not enough quarters on file yet.
How AURA moved after its last 8 reports
Average move the session after a report ±5.1%
Nov 9, 2026Time not announced+16.8%
Aug 11, 2026Time not announced+4.4%
May 4, 2026After the close+6.6%
Mar 30, 2026Time not announced−1.1%
Nov 13, 2025Time not announced−0.7%
Aug 13, 2025Time not announced+4.2%
May 15, 2025Time not announced+5.7%
Mar 24, 2025After the close+1.1%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on AURAStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on AURA
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on AURA

Technical Analysis

AURA · as of the Nov 20 close · updated each morning
Turning up

The stock is 1% above its 20 day and 5% above its 50 day average. It is sitting right on its 200 day average, a level many traders watch. Momentum is improving (RSI 51). The nearest support is the 200 day average at $6.82, and the nearest resistance the 100 day average at $6.94.

Short trendBullish
Long trendNeutral
MomentumImproving
StretchNormal
VolatilityHigh, 5.6%/day
Key levels
$9.5452 week high+38.9%
$7.31Swing high (Jul 27)+6.4%
$7.06Pivot R1+2.8%
$6.94100 day average+1.0%
$6.87Swing low (Nov 13)+0.0%
$6.87Last close
$6.82200 day average−0.7%
$6.7820 day average−1.3%
$6.78Pivot−1.3%
$6.59Pivot S1−4.1%
$6.5350 day average−4.9%
$4.7352 week low−31.1%
Indicators
RSI (14)51.20Middle of its rangeNeutral
MACD0.17Below its signal lineBearish
Stochastic52.6Middle of its rangeNeutral
ADX (14)18.7No clear trend
Williams %R-56.6Oversold below −80, overbought above −20Neutral
CCI (20)4.3Oversold below −100, overbought above 100Neutral
Rate of change+4.7%Change over 10 sessionsBullish
ATR (14)$0.39Typical daily range, 5.6% of price
MA 10Below
MA 20Above
MA 50Above
MA 100Below
MA 200Above
What happened before, for AURA

What happened before

See how AURA did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow AURA usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How AURA has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for AURAHow many large options trades hit AURA, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

AURA Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲86 buying vs 53 selling
  • ▲Held by funds +3.6 pts
  • ▲Funds holding +7
  • ●Superinvestors: 2 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding154147+4.8%
In funds' top 10220.0%
Held by funds98.1%94.5%+3.6 pts
New / increased24 / 6236 / 58−8.5%
Reduced / sold out35 / 1828 / 14+26.2%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See AURA institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AURA Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$39.9M11 sales · 7 insiders
2026-01 sold $90K2026-02 sold $529K2026-04 sold $82K2026-05 sold $39.0M2026-06 sold $82K2026-11 sold $119KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 16Janet Jill HopkinsChief Medical OfficerSale16,903$7.05$119K
Jun 16Anthony S GibneySee RemarksSale12,824$6.42$82K
May 7Matrix Capital Management Company, LP10% ownerSale6,922,870$5.64$39.0M
Apr 16Conor KilroySee RemarksSale11,738$7.02$82K
Feb 17los Pinos Elisabet deSee RemarksSale47,648$5.06$241K
Feb 17Amy ElazzouziSenior Vice President, FinanceSale8,549$5.06$43K
Every insider buy and sale for AURA over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See AURA insider trades →

From SEC Form 4 filings by AURA's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether AURA is in one of them and how their past AURA trades turned out.

AURA in the AI portfolios
Loading…

AURA News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered AURA in an article yet. Here's the latest on the wider market.

AURA in the news

About Aura Biosciences

Aura Biosciences is a biotechnology company developing drugs to treat solid tumors while aiming to preserve organ function. Its lead candidate, bel sar, is in later stage clinical trials for early choroidal melanoma, a rare eye cancer, and is also being tested in other eye cancers and in bladder cancer. Bel sar is built from modified human papilloma virus proteins linked to molecules that are activated by light, and it has not yet been approved for sale. The company is based in Boston, Massachusetts, and its intended patients are adults with these cancers.

Headquarters
Boston, MA